Company intelligence / Profile preview

Actinogen Medical Limited

Sydney, New South Wales, Australiaactinogen.com.au ↗

Ownership: Public · ACW
Employees: ~6
Development stage: Other

Overview

Demonstrated cognitive benefits in patients with early stages of Alzheimer's Disease in Phase 2 trials. The XanaMIA Phase 2b/3 trial is currently enrolling with approximately 40 patients in the treatment phase. Interim results expected in Q4 2025 and final results in second half of 2026. The drug has shown excellent safety and tolerability with no treatment-related serious adverse events reported across the development program.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

emestedastat

Financials

Market cap: $109.2M
Total revenue: $0
Enterprise value: $101M

Beyond the preview

Go deeper on Actinogen Medical Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actinogen Medical Limited.